Multiple myeloma (MM) is a rare but treatable hematological cancer, which makes Health-Related Quality of Life (HRQoL) an important patient-report outcome measure in clinical studies. The Quality o...
Background: Survival in multiple myeloma (MM) has improved in the past years with the introduction of immunomodulators and proteasome inhibitors. However, chemotherapyinduced peripheral neuropathy (CIPN) is associated with both drug classes affecting Health- Related Quality of Life (HRQoL) and activities of daily living (ADL). Objective: We evaluated CIPN in MM patients to identify associated factors and impacts on HRQoL and ADL. Methods: This is a cross-sectional study with Brazilian patients from public and private health services. Patients were interviewed using validated tools to measure CIPN and HRQoL, along with sociodemographic and clinical questions. Logistic regression was used to assess the association of CIPN with sociodemographic, clinical, and HRQoL variables. Results: In total, 217 patients were eligible for the study. The median age was 67, 50.9% were women, 51.6% had low income, 47.5% had low education, and 55.3% attended private health services. The chemotherapy regimen most used was the combination of cyclophosphamide, thalidomide, and dexamethasone (17.5%) among the 24 types of regimens found. Most patients (90.3%) had at least one CIPN symptom: 62.7% were severe, and 51.62% were extremely bothered ADL. Numbness was the most common symptom (40.6%). CIPN was independently associated with education, hospitalization, chemotherapy, side effects, disease symptoms, and global health status in HRQoL. Conclusion: MM patients showed a high frequency of CIPN, which affected ADL and impaired HRQoL. Early and accurate detection of CIPN and dose management in patients with thalidomide and bortezomib-based regimens should be performed to provide better treatment outcomes and avoid permanent disabilities.
11 February 2022 in Current Medical Research and Opinion
Objective: Multiple myeloma (MM) is an incurable hematological cancer and its treatment is geared to promote better Health-Related Quality of Life (HRQoL). We aimed to assess HRQoL and compare scores between variables on therapeutic regimens and polypharmacy in MM patients. Methods: This cross-sectional study was performed from April/2019 to February/2020 in Belo Horizonte, Brazil. HRQoL scores were obtained by the QLQ-C30 and QLQ-MY20 instruments. Data were retrieved from interviews and medical records. Therapeutic regimens were grouped into thalidomide-containing regimens; bortezomib-containing regimens; bortezomib and thalidomide-containing regimens; other therapeutic regimens, and remission group. We performed univariate analyses by the Mann-Whitney method and adopted the Kruskal-Wallis test for multiple comparisons. Robust multiple linear regression was used to determine the association between independent variables and the HRQoL scores. Results: The sample included 225 participants and most patients (65.3%) were on active treatment and had worse scores concerning future perspective. Polypharmacy was associated with worse scores on all scales in the univariate analyses. We observed a difference in the global health and body image (p < 0.05) scales in the multiple comparisons with therapeutic regimens. The global health scale difference was found between groups with other regimens and the remission group (p < 0.05). The difference between the bortezomib and thalidomide-containing regimens and remission group was not statistically significant (p = 0.077) in the body image scale. The multiple linear regression maintained the association of polypharmacy with worse HRQoL scores. Conclusion: We identified an independent association between HRQoL and polypharmacy in MM patients. However, there was no difference between the evaluated regimens, suggesting they are equivalent in Brazil about HRQoL.
Objetivos: Identificar resultados do acompanhamento farmacoterapêutico de idosos hospitalizados em uso de analgésicos opioides. Métodos: Realizou-se um estudo descritivo e retrospectivo, integrado a um Programa de Residência Multiprofissional em Saúde do Idoso. Os critérios para encaminhamento ao serviço foram estar em uso de opioides e/ou com queixa de dor. Após captação dos pacientes, realizou-se análise da farmacoterapia e, mediante necessidade, intervenções foram efetuadas. Resultados: No total, foram analisados dados referentes ao acompanhamento de 53 pacientes, com média de idade de 73 anos (desvio-padrão + 14,8). Identificaram-se 85 evoluções farmacêuticas, sendo 36 com registro de uso de opioides. Tramadol, codeína, morfina e metadona foram os opioides utilizados no grupo estudado. As principais reações adversas registradas foram constipação, náusea e vômito. Foram realizadas 26 intervenções direcionadas a esses medicamentos. Conclusão: Quando devidamente monitorados, os riscos provenientes do uso de opioides, sejam eles reais ou potenciais, são passíveis de detecção em tempo hábil, permitindo a execução de ações que previnam, amenizem ou eliminem desfechos negativos. A busca por qualificação e a cooperação entre profissionais pode auxiliar o desenvolvimento de habilidades que forneçam aos pacientes uma melhor experiência ao longo dos serviços de acompanhamento.